Ocugen, Inc. (OCGN) AI Stock Analysis

Ocugen, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing gene therapies to cure debilitating blindness diseases. Its core pipeline includes OCU400, a gene therapy aimed at restoring retinal function in inherited retinal diseases like retinitis pigmentosa and leber congenital amaurosis. It is also developing OCU410 for dry age-related macular degeneration (AMD) and OCU200, a preclinical fusion protein targeting diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen maintains strategic partnerships, including a collaboration with CanSino Biologics Inc. for gene therapy manufacturing and co-development, and an alliance with Bharat Biotech to commercialize the COVAXIN COVID-19 vaccine in the United States.

Ocugen has scaled annual revenue from $22,920 in FY2021 to $2.5M in FY2022, $6.0M in FY2023, $4.1M in FY2024, and $4.4M in FY2025, reflecting a 5-year revenue CAGR of 152.5%. However, profitability remains deeply negative due to ongoing research spending, which reached $39.8M in FY2025. In FY2025, operating margin was -1425.7% and net loss was -$67.8M, compared to a net loss of -$54.1M in FY2024. For the trailing twelve months ended June 30, 2026, revenue stood at $4.6M with an operating margin of -1105.1%, even as quarterly revenue grew 8.4% year-over-year.

As of June 30, 2026, Ocugen held $100.1M in cash and short-term investments against total debt of $88.0M, resulting in net cash of $12.1M. The company has negative shareholders' equity of -$16.6M and a current ratio of 0.80. Cash flow generation remains negative, with free cash flow of -$57.1M and operating cash flow of -$57.0M in FY2025. Capital expenditures were modest at $185,000 in FY2025, while the share count expanded 70.0% over five years to finance operations.

Ocugen trades at a price-to-sales multiple of 57.8x and an enterprise value to revenue ratio of 117.5x, well above the median of its US-listed Healthcare peers of 4.1x sales. Its forward price-to-earnings ratio is 13.1x, compared to the peer median forward P/E of 17.3x. Over the past year, Ocugen shares declined 51.6%, while the S&P 500 gained 16.8%. The stock also trades 46.9% below its 200-day moving average.

Wall Street coverage includes 5 Strong Buy and 1 Buy recommendations, with no Hold or Sell ratings. The mean price target is $12.17, representing upside of 1459.8% over the last close of $0.78. For FY2026, analysts anticipate revenue of $5.0M and EPS of -$0.24, followed by FY2027 estimates of $5.5M in revenue and -$0.25 in EPS. Ocugen has exceeded EPS estimates 0 times in the last 4 quarters, and the next earnings date is November 4, 2026.

This page is an AI-written research summary of Ocugen, Inc. (OCGN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: OCGN income statement, OCGN balance sheet, OCGN key metrics, OCGN analyst forecast, OCGN chart. See the OCGN stock overview for the latest quote and news.